Opthea Ltd (OPT) Company Annual Revenue

Corporate emblem and logo of opthea.com (OPT)

Opthea Limited competes with market behemoths by offering a patented combination therapy for the treatment of macular degeneration. The company's revenue chart demonstrates fluctuations, where the 0.00 metric reflects current dynamics. Demand for ophthalmological drugs remains independent of economic cycles, while the business's financial standing currently relies on external investment, as the clinical trial stage does not yet generate operating income.

OPT: Opthea Corp Revenue and Sales Volume 07/04/2022 - 06/28/2025

Comprehensive metric breakdowns and analytics for Opthea (OPT)

- market price and analyst price targets:
Market Price Opthea Corp|OPT - Price Target Chart
- market capitalization details:
Market Valuation Opthea Limited|OPT - Real Price to Acquire Entire Company
- business book valuation details:
Book Price of a Share Opthea|OPT - Book Capitalization|Market Value to Book Value opthea.com|OPT - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Opthea Limited|OPT - Long-Term Debt to Capital|Short-Term Debt to Capital Opthea Ltd|OPT - Company Total Debt|Debt to Net Assets Ratio Opthea Limited|OPT - Company Long-Term Debt|Company Short-Term Debt Opthea|Interim Coverage Ratio opthea.com
- earnings and valuation multiples information:
OPT - Company Net Income|Future Profit Opthea Limited|OPT - P/E Multiple|Market Cap to Projected Earnings opthea.com|OPT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Opthea Limited|OPT - Operating profit EBITDA|Net earnings per one share for the last twelve months Opthea|OPT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months opthea.com|OPT - Earnings per share growth in current year|Expected net earnings per share growth next year Opthea Limited
- company sales and revenue statistics:
OPT - Company Revenue|Company Expected Revenue Opthea Corp|OPT - Market Cap to Revenue|Price to Expected Revenue Ratio Opthea Limited
General company analysis:Opthea Corp - OPT
Original product of Opthea

Opthea Limited is developing innovative biopharmaceuticals for the treatment of retinal pathologies, where the company's sales growth rate reflects the dynamics of actual cash inflows from product sales. This indicator captures daily revenue volume, allowing investors to objectively assess the stability of demand for sozinibercept and the commercial effectiveness of the VEGF-C/D pathway inhibition strategy amid market volatility.

Analysis of competing companies

Company Total Revenue Alcon Corp ALC|Company Revenue Bausch + Lomb Corporation (BLCO)|GKOS: Company Annual Revenue|Apellis - Company Sales|Company Total Sales BLTE (Belite Bio Corp)|Ocular Therapeutix Corp - Revenue and Sales Volume|Company Sales Revenue HROW (Harrow Corp)|VRDN: Revenue and Sales Volume|Company Total Revenue lenz-tx.com (LENZ)|OCS (Oculis Holding AG) - Revenue and Sales Volume|Revenue and Sales Volume EyePoint Pharmaceuticals Inc|Company Sales KOD (Kodiak Pharma)|ALDX (aldeyra.com) - Company Sales Revenue|Company Revenue KALA BIO KALA|Opus Genetics, Inc. - Company Revenue|OKYO Pharma Inc - Revenue and Sales Volume|Company Gross Revenue Adverum Biotechnologies ADVM|Outlook Pharma (OTLK) - Company Revenue|Company Sales Clearside Corp|NBY (NovaBay Pharmaceuticals Inc.) - Revenue and Sales Volume|Kiora Pharma (KPRX) - Company Gross Revenue|Company Sales ALIM (Alimera Sciences)|Company Total Sales EYEN|Revenue and Sales Volume GHSI (Guardion Health Sciences Inc.)|Ocuphire Corporation (OCUP) - Company Total Revenue